Skip to content

The Effect of vaginal Bromocriptine in controlling Adenomyosis symptoms

The Effect of vaginal Bromocriptine in controlling Adenomyosis symptoms

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12617001122347
Enrollment
68
Registered
2017-07-31
Start date
2019-02-05
Completion date
Unknown
Last updated
2018-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Hysterectomy (removal of womb and ovaries)considered the most common treatment for symptomatic adenomyosis. However due to its association with perioperative , postoperative morbidity, decreased quality of life and high healthcare costs,it looks wise to find another non surgical treatment. Hysterectomy is also not appropriate for women who wish to preserve their fertility and availability of a noninvasive approach for the treatment of adenomyosis may be preferable for most women and could reduce the burden on healthcare systems by a major reduction in surgical intervention. Untill now no proved evidence for any mode of treatment. this study tried to find appropriate medical treatment for this problem.

Interventions

vaginal bromocriptine suppository 0.5 mg twice daily inserted by patient for six months, the patient will be phoned monthly to monitor adherence to the intervention

Sponsors

Nahed ezzat allam
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
23 Years to 49 Years
Healthy volunteers
No

Inclusion criteria

women complaining of symptoms related to presence of adenomyosis like dysmenorrhea, menstrual irregularities and or subfertility.

Exclusion criteria

1-Patients on hormonal or intrauterine device as contraception 2-Active pelvic infection 3- Pregnant or breast fed women 4-Hypersenstivity or contraindication to bromocriptine, 5-local contraception users

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026